Skip to main content

Deal with US drug company raises controversy in Egypt over use of anti-coronavirus treatment

Egypt’s Eva Pharma reached a deal with Gilead Sciences to locally manufacture the antiviral treatment Remdesivir for the treatment of coronavirus patients and distribute it in 127 countries.

CAIRO — Egypt’s Ministry of Health announced June 19 that the local production of Remdesivir, the antiviral treatment for the coronavirus, will start at the end of this month.

The announcement came after Egyptian drugmaker Eva Pharma announced June 14 that it had reached a deal with the American biopharmaceutical company Gilead Sciences, Inc., to become the licensed manufacturer of the US company’s Remdesivir. Eva Pharma will distribute the product in 127 countries, including Egypt.

Access the Middle East news and analysis you can trust

Join our community of Middle East readers to experience all of Al-Monitor, including 24/7 news, analyses, memos, reports and newsletters.


Only $100 per year.